Novartis signs mRNA deal for about $7.8 billion with China's Abogen

By Reuters News

- Chinese biotech company Abogen said on Friday it signed a licensing deal worth about $7.8 billion with Swiss drug maker Novartis NOVN.S to advance RNA-based therapy.

Novartis will gain exclusive rights to Abogen's experimental drug, ABO2203, and options to license other therapies based on Abogen's RNA technology. It will also have the option to license additional experimental medicines developed using Abogen's RNA platform.

Under the deal, Abogen will receive $575 million upfront with the potential to earn an additional $7.2 billion if the drug advances through development and wins regulatory approval.

ABO2203 is designed to treat autoimmune diseases by targeting B cells, a type of immune cell that causes disease in conditions like lupus and rheumatoid arthritis.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk